Introduction
Lymphomatoid Granulomatosis (LYG) is an extremely rare Epstein-Barr virus (EBV)-associated lymphoproliferative disorder. While it primarily targets the lungs—occurring in nearly 100% of cases—it can also affect the skin, central nervous system, and kidneys. Because its symptoms often mimic other malignancies or inflammatory conditions, LYG is notoriously difficult to diagnose. This case report details a rare instance of LYG that first appeared as a gastric lesion and remained undiagnosed for six years before manifesting in the lungs.
Case Presentation
In July 2009, a 63-year-old woman was flagged for abnormalities during an upper gastrointestinal series. Subsequent endoscopy revealed a significant gastric lesion. Despite 18 biopsy sessions over the following five years, a definitive diagnosis remained elusive. Curiously, the gastric lesion appeared to undergo spontaneous regression, a deceptive "honeymoon period" that led clinicians away from a malignant diagnosis.
In early 2015, the disease returned in a more aggressive, multi-organ form. Computed Tomography (CT) scans revealed multiple lung masses and abdominal lymphadenopathy. To obtain a definitive diagnosis, the patient underwent a thoracoscopic partial resection of the left lower lung lobe.
Pathological Insights and Diagnosis
Histopathological examination of the resected lung tissue revealed an "angiodestructive" growth pattern, where lymphoid cells were found infiltrating muscular arteries and veins. To confirm the diagnosis of Grade 1 LYG, the team used in situ hybridization to detect EBV-encoded small RNA (EBER), identifying the hallmark EBV-infected B-cells.
Following the lung diagnosis, the authors retrospectively re-examined the original 2009 gastric biopsy samples using these specialized staining techniques. This analysis confirmed that the stomach lesion was indeed the primary manifestation of the same LYG process, highlighting the disease's systemic nature and its ability to present in the gastrointestinal tract—a very rare site.
Treatment and Clinical Outcome
As the disease had progressed to involve both the lungs and the liver, the patient began a systemic chemotherapy regimen of R-THP-COP (Rituximab, Pirarubicin, Cyclophosphamide, Vincristine, and Prednisolone). After three courses of treatment, follow-up CT scans showed a partial response (PR), with significant shrinkage of the lesions in the lungs, liver, and lymph nodes.
Conclusion
This case emphasizes that LYG is not strictly a pulmonary disease and can present with atypical extra-pulmonary symptoms that may spontaneously regress. The authors advocate for a high index of suspicion when faced with atypical lymphoproliferative lesions in the stomach. Furthermore, because standard endoscopic biopsies often provide insufficient tissue, larger samples (via ESD, EMR, or surgical resection) may be necessary to identify the characteristic vascular infiltration required for a definitive diagnosis.
Summary updated